We Help Make Dialysis Care HappenWhen you partner with Fresenius Medical Care Renal Therapies Group (RTG), you get 30-plus years of renal therapies expertise. You get a product portfolio that covers nearly every aspect of dialysis care and many of the most recognized product names in the industry. You get exceptional customer service and a truly reliable supply chain. In short, you get what you need when you need it, so your patients can too.

SITUATION: “FAST EMERGING EPIDEMIC”Finally, the medical community and the public are fast becoming aware of the major harm that can result from concussions (also referred to as Mild Traumatic Brain Injury-mTBI). PROBLEM: “HUGE UNMET CLINICAL NEED with not objective solution” With all of today’s advanced medical technology, acute concussion is still being diagnosed with subjective, symptom-based tests (balancing on one foot, asking questions) some are 30+ years old. CT imaging is NOT a concussion test and only used to rule out major brain bleeds. SOLUTION: “OBJECTIVE BIOLOGICAL DETECTION WITH A DROP OF BLOOD IN 90 SECONDS”For the past seven years, BioDirection has been developing a biological approach combined with a

Created all key elements of the global strategic plan. Worked with the cardiovascular surgeons, cardiologist, executive management and cross functional teams to develop the global strategic plan. The components of the plan encompass: Understanding of the sweeping healthcare dynamics specifically the impact on global providers, development and analysis of primary and secondary research, establishing strategic objectives for multiple audiences in the local, regional, national and international market segments, and identification of the strategic initiatives and success metric to achieve objectives.T

Brought in as the global director within the newly formed Vascular Therapies Division, revenue of $600+ million. Responsible for the global renal business unit, reporting to the V.P. /GM of the VT division. Led and implemented a new strategic plan and product lifecycle process, significantly shifted funding and resources to the vital programs with the largest ROI. Chaired the global portfolio management team, a cross-functional executive group responsible for funding and execution of all new product development. Selected accomplishments include:•Led the development of the global strategic plan for the renal business unit, support by primary and secondary market research. Resulted in: The identification of two new emerging markets with a $250+ million upside.•Expanded KOL relationships in the specialties of: nephrology, interventional radiology and vascular surgery.•Developed the global business plans and financial justifications for four new strategic programs with potential revenue of over $250 million and a combined net present value of $100+ million. •

EVP/President of the Endovascular Forum reporting to the CEO. The Forum is now one of the world’s largest doctor-to-doctor on-line portal for Interventional cardiologist, radiologist & vascular surgeons, enabling physicians to virtually exchange, in real-time, clinical experiences and complex cases globally in over 150 countries. Over 40% of physicians are from international markets. Selected accomplishments include:•Through primary research with emphasis on KOL input, identified multiple unmet user needs. Led a cross-functional software team that transformed theses needs from concept to new product launches. This allowed the EVF platform to shift its technology lifecycle position from the declining stage to the innovation stage. •Forged partnerships with three major medical societies and KOL physician leadership in Interventional radiology, cardiology, and vascular medicine. This strategic move resulted in growing user base 300% from 3,000 physicians to 10,000+ in 10 months, largest increase in six years combined.•Created and marketed a value proposition for the endovascular forum which resulted in securing the first revenue in more than three years from a $10 billion medical company

•Founded a marketing consulting company focused on tactical marketing plans for small/medium businesses.

Selected by SVP/Chief Technology Officer to build and drive the strategic/tactical marketing and product development of the second largest program at BSC. Reported to the GM. Built and mentored a team of six direct reports; Overall program was resourced with 150+ people and an operating budget of $80 million. Selected accomplishments include:•Led a cross-functional global product development team in development of a fully digital, disposable endoscope and hardware/software platform product from concept to first-human use.•Expanded key relationships to include KOL’s in gastroenterology.••Built and mentored a project management team of six direct reports, executed through a complex cross-functional stage gate Product Development Process. Teams from Natick/Cambridge, MA; Huntsville, AL; Canada; India.

Lead all aspects of two next-generation peripheral vascular stent programs (the NIR® stent and Express® SD) from strategic business plan to global product launch and commercialization. Reported to the SVP/Chief Technology Officer. Responsible for direct interface with executive committee; led a team of 25+ and managed an operating budget of $5 million. Selected accomplishments include:•Led cross-functional vascular stent from concept to global launch in 15 months, 33% ahead of company metrics.•Wrote the first BSC strategic plan on stent treatment for renal vascular disease supported by Voice Of Customer research, targeted KOL’s in cardiology, radiology and vascular surgery. •Led a 20+ member cross-functional project management team in the development and global launch of: the next generation Express® SD stent, the Maverick®XL coronary balloon and the Maverick® Monorail® peripheral balloon. •Headed a team including 8 physican KOL’s that developed and executed the first clinical trial for a renal indication on the Express® SD Renal Monorail® Premounted Stent System.

Selected by the Group President to form and lead a new division focused on technologies to treat vascular diseases of the brain. Built and mentored a team of 20+, shaped all facets of new division - culture, R&D portfolio, cross-functional effectiveness and global product launches. Reported to the president. Selected accomplishmentsinclude: •Led VOC and KOL relationships in novel treatment for aneurysm repair with thermal and radiation energy. •Formed relationships with KOL’s in neurosurgery and interventional radiology both U.S. and international.•Over saw the product develop process. In 24 months launched five new products: Renegade™ microcatheter, In-time™ stroke device, Eddy™ flow catheter, Glidewire® gold, and Transend™, g•Wrote the strategic and annual business plans for the new division. Created a divisional branding strategy that resulted in multiple national medical branding awards and captured share of mind with the customers.

Promoted to position of Group Marketing Manager with six direct reports and reporting to the VP.Accountable for leading an $82 million vascular and non-vascular business, 73% of Divisions revenues. Selected accomplishments include:•Headed multiple cross-functional teams to over 15 new global product launches.•Awarded the first-ever Boston Scientific “special stock grant award” from the COO, Joe Ciffolillo.